von Willebrand factor A1 domain – Platelet glycoprotein Ib interaction (vWF-A1:GPIb)

The interaction between the von Willebrand factor (vWF) A1 domain and the platelet glycoprotein Ib (GPIb) complex is a fundamental mechanism in primary hemostasis, specifically mediating platelet adhesion to the subendothelium under high shear stress conditions (UniProt P04275). When blood vessels are damaged, vWF undergoes a conformational change that exposes the A1 domain, which then binds to the N-terminal leucine-rich repeat domain of the GPIbα subunit on platelets (PubMed: 24523240). This transient tethering or rolling is essential for subsequent stable platelet aggregation and thrombus formation. Pathological activation of this interaction is a key driver in thrombotic thrombocytopenic purpura (TTP) and arterial thrombosis, while its deficiency results in bleeding disorders such as von Willebrand disease (PubMed: 28232467). Therapeutic agents like caplacizumab, a bivalent nanobody, specifically target the vWF A1 domain to block this interaction, thereby preventing the formation of microvascular thrombi in patients with acquired TTP (FDA, 2019). Other investigational drugs have targeted this axis to treat acute coronary syndromes and stroke, aiming to provide antithrombotic efficacy with a potentially lower bleeding risk compared to traditional antiplatelet therapies (PubMed: 25655600).

Other names

vWF-GPIb axisvWF-GPIbα interactionPlatelet glycoprotein Ib-von Willebrand factor interactionvWF:GPIb-IX-V interaction

Inhibition of the interaction between the vWF A1 domain and the platelet GPIbα receptor to prevent platelet tethering and adhesion under high shear stress.